search
Back to results

Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years

Primary Purpose

Alcohol-Related Disorders, Substance-Related Disorders, Mental Health

Status
Not yet recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Screening, Brief Intervention, and Referral to Treatment (SBIRT)
Sponsored by
Columbia University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alcohol-Related Disorders focused on measuring Implementation Science, Mass Screening, Motivational Interviewing, Referral and Consultation, Quality of Health Care, Early Medical Intervention, Family Planning Services, Primary Health Care, Reproductive Health Services, Telemedicine, Preconception Care, Young Adult

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Over the age of 18 years U.S. residing Have internet access (own a computer or smart phone) Screen positive to one or more risky alcohol and substance use behaviors as determined by our standardized abbreviated instruments Exclusion Criteria: - Not capable of communicating (reading, speaking, writing) in English or Spanish

Sites / Locations

  • Greater Boston Health Center
  • Metro West Health Center
  • Western Massachusetts Health Center
  • Central Massachusetts Health Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

SBIRT

Usual Care

Arm Description

Screening, Brief Intervention, and Referral to Treatment (SBIRT) is an evidence-based approach supported by national healthcare organizations, including the Preventative Services Task Force and the American College of Obstetrics and Gynecologists. Validated tools (AUDIT-C and NIDA ASSIST) will efficiently screen an individual's substance use risk. Patients who screen in the risky/harmful range then receive a brief motivational interviewing-based intervention adapted from the evidence-based Brief Negotiated Interview, lasting 5-10 minutes, which provides feedback, helps explore health risks, and motivates change. Individuals who screen in the severe category, indicating a likely AUD/SUD, also receive a brief intervention, aimed at increasing motivation to accept a referral to treatment, and requiring a more intensive approach will also receive a warm-hand off referral to specialty addiction treatment.

None of the clinic sites have implemented standardized screening, brief intervention, or referral to treatment components. In this setting, usual care consists of basic quantity and frequency questions asked inconsistently as part of the admission process and varying by provider, with no standardized approach to screening, treatment, follow-up, or referral.

Outcomes

Primary Outcome Measures

Average drinks per drinking day (T0)
Average number of drinks consumed on days where individual consumed alcohol (past 30 days)
Average drinks per drinking day (T1)
Average number of drinks consumed on days where individual consumed alcohol (past 30 days)
Average drinks per drinking day (T2)
Average number of drinks consumed on days where individual consumed alcohol (past 30 days)
Depression score (T0)
Score on the depression scale from the Patient Health Questionnaire (PHQ-9), which measures depression severity in past 14 days. Scores can range from 0 to 27, with scores of 0-4 classified as minimal depression, 5-9 as mild depression; 10-14 as moderate depression; 15-19 as moderately severe depression, and ≥ 20 as severe depression). Each item on the scale can be scored from 0 (not at all) to 3 (nearly everyday).
Depression score (T1)
Score on the depression scale from the Patient Health Questionnaire (PHQ-9), which measures depression severity in past 14 days. Scores can range from 0 to 27, with scores of 0-4 classified as minimal depression, 5-9 as mild depression; 10-14 as moderate depression; 15-19 as moderately severe depression, and ≥ 20 as severe depression). Each item on the scale can be scored from 0 (not at all) to 3 (nearly everyday).
Depression score (T2)
Score on the depression scale from the Patient Health Questionnaire (PHQ-9), which measures depression severity in past 14 days. Scores can range from 0 to 27, with scores of 0-4 classified as minimal depression, 5-9 as mild depression; 10-14 as moderate depression; 15-19 as moderately severe depression, and ≥ 20 as severe depression). Each item on the scale can be scored from 0 (not at all) to 3 (nearly everyday).
Fidelity - BIOS score for audio recordings (1)
Mean score on the first 10 items of the Brief Intervention Observation Sheet (BIOS) per provider from a sample of audio recorded brief interventions (BI). Scores can range from 0-10, with higher scores indicating better performance.
Fidelity - BIOS score for audio recordings (2)
Mean score on the 11th item of the Brief Intervention Observation Sheet (BIOS) per provider from a sample of audio recorded brief interventions (BI). The 11th item reflects how well the provider use a motivational style. Scores can range from 1-7, with higher scores indicating better performance.
Incidence of sex under influence of alcohol/drugs (T0)
Any incidence of sex under influence of alcohol/drugs in past 30 days
Incidence of sex under influence of alcohol/drugs (T1)
Any incidence of sex under influence of alcohol/drugs in past 30 days
Incidence of sex under influence of alcohol/drugs (T2)
Any incidence of sex under influence of alcohol/drugs in past 30 days
Number of days of drug use (T0)
Number of days of drug use in past 30 days
Number of days of drug use (T1)
Number of days of drug use in past 30 days
Number of days of drug use (T2)
Number of days of drug use in past 30 days
Number of events of sex under influence of alcohol/drugs (T0)
Number of events of sex under influence of alcohol/drugs in past 30 days
Number of events of sex under influence of alcohol/drugs (T1)
Number of events of sex under influence of alcohol/drugs in past 30 days
Number of events of sex under influence of alcohol/drugs (T2)
Number of events of sex under influence of alcohol/drugs in past 30 days
Number of recordings to achieve competency
Number of audio recordings needed to achieve competency as rated by SBIRT trainers using the Brief Intervention Observation Sheet (BIOS)
Patients receiving BI (IP)
Percent of patients in each clinic out of all who screen positive, who receive a brief intervention during the implementation phase (IP)
Patients receiving BI (SP)
Patients receiving BI (SP)
SBIRT use (IP)
Number/proportion of providers in each clinic using SBIRT (implementation phase)
SBIRT use (SP)
Number/proportion of clinics and of providers in each clinic using SBIRT (sustainment phase)

Secondary Outcome Measures

AUDIT-C score (T0)
Score on screening measure for risky drinking; adjusted to past 30 days. The Alcohol Use Disorders Identification Test-Concise (AUDIT-C) is a brief alcohol screening instrument that reliably identifies persons who are hazardous drinkers or have active alcohol use disorders (including alcohol abuse or dependence). The AUDIT-C is a modified version of the 10 question AUDIT instrument. The AUDIT-C has 3 questions and is scored on a scale of 0-12. Each AUDIT-C question has 5 answer choices valued from 0 points to 4 points. In men, a score of 4 or more is considered positive, optimal for identifying hazardous drinking or active alcohol use disorders. In women, a score of 3 or more is considered positive. Generally, the higher the score, the more likely it is that a person's drinking is affecting his or her safety.
AUDIT-C score (T1)
Score on screening measure for risky drinking; adjusted to past 30 days. The Alcohol Use Disorders Identification Test-Concise (AUDIT-C) is a brief alcohol screening instrument that reliably identifies persons who are hazardous drinkers or have active alcohol use disorders (including alcohol abuse or dependence). The AUDIT-C is a modified version of the 10 question AUDIT instrument. The AUDIT-C has 3 questions and is scored on a scale of 0-12. Each AUDIT-C question has 5 answer choices valued from 0 points to 4 points. In men, a score of 4 or more is considered positive, optimal for identifying hazardous drinking or active alcohol use disorders. In women, a score of 3 or more is considered positive. Generally, the higher the score, the more likely it is that a person's drinking is affecting his or her safety.
AUDIT-C score (T2)
Score on screening measure for risky drinking; adjusted to past 30 days. The Alcohol Use Disorders Identification Test-Concise (AUDIT-C) is a brief alcohol screening instrument that reliably identifies persons who are hazardous drinkers or have active alcohol use disorders (including alcohol abuse or dependence). The AUDIT-C is a modified version of the 10 question AUDIT instrument. The AUDIT-C has 3 questions and is scored on a scale of 0-12. Each AUDIT-C question has 5 answer choices valued from 0 points to 4 points. In men, a score of 4 or more is considered positive, optimal for identifying hazardous drinking or active alcohol use disorders. In women, a score of 3 or more is considered positive. Generally, the higher the score, the more likely it is that a person's drinking is affecting his or her safety.
Anxiety score (T0)
Score on the Generalized Anxiety Disorder 7-item (GAD-7) scale, which measures anxiety severity. Each item is scored on a scale of 0 (not at all) to 3 (nearly every day), with higher scores indicating higher levels of anxiety based on past 14 days. A score of 0-4 is classified as minimal anxiety, 5-9 as mild anxiety, 10-14 as moderate anxiety, and as 15-21 severe anxiety.
Anxiety score (T1)
Score on the Generalized Anxiety Disorder 7-item (GAD-7) scale, which measures anxiety severity. Each item is scored on a scale of 0 (not at all) to 3 (nearly every day), with higher scores indicating higher levels of anxiety based on past 14 days. A score of 0-4 is classified as minimal anxiety, 5-9 as mild anxiety, 10-14 as moderate anxiety, and as 15-21 severe anxiety.
Anxiety score (T2)
Score on the Generalized Anxiety Disorder 7-item (GAD-7) scale, which measures anxiety severity. Each item is scored on a scale of 0 (not at all) to 3 (nearly every day), with higher scores indicating higher levels of anxiety based on past 14 days. A score of 0-4 is classified as minimal anxiety, 5-9 as mild anxiety, 10-14 as moderate anxiety, and as 15-21 severe anxiety.
BIOS score (1)
Each provider's score on the first 10 items of the Brief Intervention Observation Sheet (BIOS) on the last observation conducted during provider training. Scores can range from 0-10, with higher scores indicating better performance.
BIOS score (2)
Each provider's score on the 11th item of the Brief Intervention Observation Sheet (BIOS) on the last observation conducted during provider training. Scores can range from 1-7, with higher scores indicating better performance.
Days of alcohol use (T0)
Number of days of alcohol use in past 30 days
Days of alcohol use (T1)
Number of days of alcohol use in past 30 days
Days of alcohol use (T2)
Number of days of alcohol use in past 30 days
Days of binge drinking (T0)
Number of days of binge drinking (defined as 4 or more drinks) in past 30 days
Days of binge drinking (T1)
Number of days of binge drinking (defined as 4 or more drinks) in past 30 days
Days of binge drinking (T2)
Number of days of binge drinking (defined as 4 or more drinks) in past 30 days
General self-reported health (T0)
Likert rating of general self-reported health in past 30 days
General self-reported health (T1)
Likert rating of general self-reported health in past 30 days
General self-reported health (T2)
Likert rating of general self-reported health in past 30 days
Incidence of condom nonuse (T0)
Any incidence of condom nonuse monogamous encounters among women not intending pregnancy in past 30 days
Incidence of condom nonuse (T1)
Any incidence of condom nonuse monogamous encounters among women not intending pregnancy in past 30 days
Incidence of condom nonuse (T2)
Any incidence of condom nonuse monogamous encounters among women not intending pregnancy in past 30 days
Incidence of contraceptive nonuse (T0)
Any incidence of contraceptive nonuse monogamous encounters among women not intending pregnancy in past 30 days
Incidence of contraceptive nonuse (T1)
Any incidence of contraceptive nonuse monogamous encounters among women not intending pregnancy in past 30 days
Incidence of contraceptive nonuse (T2)
Any incidence of contraceptive nonuse monogamous encounters among women not intending pregnancy in past 30 days
Incidence of regretted/nonconsensual sex and sexual violence (T0)
Any incidence of non-consensual sex, regretted sex, or sexual violence in past 30 days
Incidence of regretted/nonconsensual sex and sexual violence (T1)
Any incidence of non-consensual sex, regretted sex, or sexual violence in past 30 days
Incidence of regretted/nonconsensual sex and sexual violence (T2)
Any incidence of non-consensual sex, regretted sex, or sexual violence in past 30 days
NIDA ASSIST score (T0)
Score on the National Institute of Drug Addiction-Modified Alcohol, Smoking and Substance Involvement Screening Test (NIDA-Modified ASSIST) screening measure for risky drinking; adjusted to past 30 days. Scores range from 0 to 390, with higher scores indicating greater risk. A score of 0-3 is considered lower risk, 4-26 is considered moderate risk, and 27 and over is considered high risk.
NIDA ASSIST score (T1)
Score on the National Institute of Drug Addiction-Modified Alcohol, Smoking and Substance Involvement Screening Test (NIDA-Modified ASSIST) screening measure for risky drinking; adjusted to past 30 days. Scores range from 0 to 390, with higher scores indicating greater risk. A score of 0-3 is considered lower risk, 4-26 is considered moderate risk, and 27 and over is considered high risk.
NIDA ASSIST score (T2)
Score on the National Institute of Drug Addiction-Modified Alcohol, Smoking and Substance Involvement Screening Test (NIDA-Modified ASSIST) screening measure for risky drinking; adjusted to past 30 days. Scores range from 0 to 390, with higher scores indicating greater risk. A score of 0-3 is considered lower risk, 4-26 is considered moderate risk, and 27 and over is considered high risk.
Number of events of condom nonuse (T0)
Number of events of condom nonuse monogamous encounters among women not intending pregnancy in past 30 days
Number of events of condom nonuse (T1)
Number of events of condom nonuse monogamous encounters among women not intending pregnancy in past 30 days
Number of events of condom nonuse (T2)
Number of events of condom nonuse monogamous encounters among women not intending pregnancy in past 30 days
Number of events of contraceptive nonuse (T0)
Number of events of contraceptive nonuse monogamous encounters among women not intending pregnancy in past 30 days
Number of events of contraceptive nonuse (T1)
Number of events of contraceptive nonuse monogamous encounters among women not intending pregnancy in past 30 days
Number of events of contraceptive nonuse (T2)
Number of events of contraceptive nonuse monogamous encounters among women not intending pregnancy in past 30 days
Number of events of regretted/nonconsensual sex and sexual violence (T0)
Number of events of non-consensual sex, regretted sex, or sexual violence in past 30 days
Number of events of regretted/nonconsensual sex and sexual violence (T1)
Number of events of non-consensual sex, regretted sex, or sexual violence in past 30 days
Number of events of regretted/nonconsensual sex and sexual violence (T2)
Number of events of non-consensual sex, regretted sex, or sexual violence in past 30 days
Patients receiving referral (IP)
Percent of patients who screen at a severe level of alcohol use, who receive a referral during the implementation phase (IP)
Patients receiving referral (SP)
Percent of patients who screen at a severe level of alcohol use, who receive a referral during the sustainment phase (SP)
Patients screened (IP)
Percent of patients out of all patients seen who are screened during the implementation phase (IP)
Patients screened (SP)
Percent of patients out of all patients seen who are screened during the sustainment phase (SP)
Quality of life score (T0)
Score on the 12-Item Short Form Health Survey, which measures physical and mental health functioning in past 30 days. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.
Quality of life score (T1)
Score on the 12-Item Short Form Health Survey, which measures physical and mental health functioning in past 30 days. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.
Quality of life score (T2)
Score on the 12-Item Short Form Health Survey, which measures physical and mental health functioning in past 30 days. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.
SBIRT knowledge
Score on University of Missouri-Kansas City Screening & Brief Intervention Knowledge Assessment. Will b be completed by providers undergoing training in SBIRT. Scores range from 0-20, with higher scores indicating more knowledge of SBIRT.
STI incidence (T0)
Any incidence of a sexually transmitted infection (STI) in past 30 days
STI incidence (T1)
Any incidence of a sexually transmitted infection (STI) in past 30 days
STI incidence (T2)
Any incidence of a sexually transmitted infection (STI) in past 30 days
Unintended pregnancy (T0)
Any incidence of unintended pregnancy in past 30 days
Unintended pregnancy (T1)
Any incidence of unintended pregnancy in past 30 days
Unintended pregnancy (T2)
Any incidence of unintended pregnancy in past 30 days
Well-being score (T0)
Score on the World Health Organization-Five Well-Being Index (WHO-5), a five-item scale that measures subjective psychological well-being in past 14 days. Scores range from 0-5, with 0 representing the worst possible and 25 representing the best possible quality of life.
Well-being score (T1)
Score on the World Health Organization-Five Well-Being Index (WHO-5), a five-item scale that measures subjective psychological well-being in past 14 days. Scores range from 0-5, with 0 representing the worst possible and 25 representing the best possible quality of life.
Well-being score (T2)
Score on the World Health Organization-Five Well-Being Index (WHO-5), a five-item scale that measures subjective psychological well-being in past 14 days. Scores range from 0-5, with 0 representing the worst possible and 25 representing the best possible quality of life.

Full Information

First Posted
May 19, 2023
Last Updated
July 10, 2023
Sponsor
Columbia University
Collaborators
National Institute on Alcohol Abuse and Alcoholism (NIAAA), Emory University, Stanford University, Planned Parenthood League of Massachusetts
search

1. Study Identification

Unique Protocol Identification Number
NCT05910580
Brief Title
Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years
Official Title
Improving Alcohol and Substance Use Care Access, Outcomes, and Equity During the Reproductive Years: A Type 1 Hybrid Trial in Family Planning Clinics
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
April 1, 2024 (Anticipated)
Primary Completion Date
May 31, 2026 (Anticipated)
Study Completion Date
May 31, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Columbia University
Collaborators
National Institute on Alcohol Abuse and Alcoholism (NIAAA), Emory University, Stanford University, Planned Parenthood League of Massachusetts

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this clinical trial is to test the effectiveness of evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) among adult patients who screen positive to one or more risky alcohol or substance use behaviors while seeking care at a sexual and reproductive health (SRH) clinic. The main questions it aims to answer are: Does SBIRT impact patients' alcohol and substance use, SRH, mental health, physical health, quality of life, and wellbeing? Does SBIRT effectiveness differ by ethnicity, socioeconomic status, age, gender, and urbanicity? Does SBIRT effectiveness differ by delivery mode (in-person vs. telemedicine)? Participants will receive in-person SBIRT, telemedicine SBIRT, or usual care. Participants will complete surveys at interviews at baseline, 30 days, and 3 months. Researchers will compare patients who received SBIRT to patients who receive usual care to see if patients who receive the SBIRT intervention have a greater reduction in negative outcomes as compared to those who receive usual care. In this setting, usual care consists of basic quantity and frequency questions asked inconsistently as part of the admission process and varying by provider, with no standardized approach to screening, treatment, follow-up, or referral.
Detailed Description
Risky alcohol and drug use are associated with severe, negative, and long-term health outcomes and disparities, including sexual and reproductive health (SRH), among reproductive aged people in the United States. High rates and sequelae of alcohol and drug use disproportionately experienced by structurally marginalized groups shape lifelong health inequities for people of racial/ethnic minority, living in poverty, and residing in under-resourced and under-served communities. Among populations at risk of pregnancy-related sequelae (predominantly those self-identifying as women and thus this study's primary focus), harmful alcohol and substance use and alcohol use disorders (AUDs)/substance use disorders (SUDs) contribute to condom and contraceptive nonuse among those not intending pregnancy, sex while intoxicated, non-consensual sex, violence/rape, sexually transmitted infections, unintended pregnancy, and maternal and infant morbidity and mortality. Family planning (FP) clinics are uniquely well-suited but entirely untapped sites for implementing and scaling integrated alcohol/substance use services. Largely community-based health centers that are publicly funded and/or serve Medicaid enrollees, FP clinics are a trusted care source and primary access point for reproductive aged women, and a safety net for the most socially disadvantaged groups. Yet few, if any, studies have rigorously evaluated interventions or implementation strategies to accelerate the uptake of alcohol/substance services in FP contexts. In obstetrics and HIV, widespread adoption of evidence-based SBIRT (screening, brief intervention, and referral to treatment) is precluded by multi-level barriers; data on specific challenges faced by FP providers are lacking. Virtually nothing is known about telemedicine, which has been rolled out for contraception and other routine visits during the pandemic, as a technological infrastructure for SBIRT. Whether and how the promising strategy of Implementation and Sustainment Facilitation (ISF) can bridge systems barriers and support scale up in FP settings is unknown. The researchers propose an explanatory, sequential, mixed methods study of alcohol and drug SBIRT in an expansive FP clinic network - a novel and highly impactful setting with a national reach of a diverse and largely structurally disadvantaged population of reproductive-aged women at greatest risk for AUDs/SUDs. The researchers will conduct a randomized Type 1 Hybrid Effectiveness-Implementation Trial within a large Northeastern regional affiliate and its four clinics of a national SRH care organization. Results will inform an evidence-based, innovative, stakeholder-driven FP SBIRT model in response to the high-level calls for integrated women's health care. With concrete guidance for scaling alcohol/ drug services in SRH settings nationally, findings will promote women's health equity across the U.S.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alcohol-Related Disorders, Substance-Related Disorders, Mental Health, Reproductive Health, Sexual Health, Sexually Transmitted Diseases, Contraception, Maternal Health, Pregnancy, Women's Health
Keywords
Implementation Science, Mass Screening, Motivational Interviewing, Referral and Consultation, Quality of Health Care, Early Medical Intervention, Family Planning Services, Primary Health Care, Reproductive Health Services, Telemedicine, Preconception Care, Young Adult

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
600 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
SBIRT
Arm Type
Experimental
Arm Description
Screening, Brief Intervention, and Referral to Treatment (SBIRT) is an evidence-based approach supported by national healthcare organizations, including the Preventative Services Task Force and the American College of Obstetrics and Gynecologists. Validated tools (AUDIT-C and NIDA ASSIST) will efficiently screen an individual's substance use risk. Patients who screen in the risky/harmful range then receive a brief motivational interviewing-based intervention adapted from the evidence-based Brief Negotiated Interview, lasting 5-10 minutes, which provides feedback, helps explore health risks, and motivates change. Individuals who screen in the severe category, indicating a likely AUD/SUD, also receive a brief intervention, aimed at increasing motivation to accept a referral to treatment, and requiring a more intensive approach will also receive a warm-hand off referral to specialty addiction treatment.
Arm Title
Usual Care
Arm Type
No Intervention
Arm Description
None of the clinic sites have implemented standardized screening, brief intervention, or referral to treatment components. In this setting, usual care consists of basic quantity and frequency questions asked inconsistently as part of the admission process and varying by provider, with no standardized approach to screening, treatment, follow-up, or referral.
Intervention Type
Behavioral
Intervention Name(s)
Screening, Brief Intervention, and Referral to Treatment (SBIRT)
Intervention Description
See SBIRT arm description.
Primary Outcome Measure Information:
Title
Average drinks per drinking day (T0)
Description
Average number of drinks consumed on days where individual consumed alcohol (past 30 days)
Time Frame
Baseline
Title
Average drinks per drinking day (T1)
Description
Average number of drinks consumed on days where individual consumed alcohol (past 30 days)
Time Frame
30 days
Title
Average drinks per drinking day (T2)
Description
Average number of drinks consumed on days where individual consumed alcohol (past 30 days)
Time Frame
3 months
Title
Depression score (T0)
Description
Score on the depression scale from the Patient Health Questionnaire (PHQ-9), which measures depression severity in past 14 days. Scores can range from 0 to 27, with scores of 0-4 classified as minimal depression, 5-9 as mild depression; 10-14 as moderate depression; 15-19 as moderately severe depression, and ≥ 20 as severe depression). Each item on the scale can be scored from 0 (not at all) to 3 (nearly everyday).
Time Frame
Baseline
Title
Depression score (T1)
Description
Score on the depression scale from the Patient Health Questionnaire (PHQ-9), which measures depression severity in past 14 days. Scores can range from 0 to 27, with scores of 0-4 classified as minimal depression, 5-9 as mild depression; 10-14 as moderate depression; 15-19 as moderately severe depression, and ≥ 20 as severe depression). Each item on the scale can be scored from 0 (not at all) to 3 (nearly everyday).
Time Frame
30 days
Title
Depression score (T2)
Description
Score on the depression scale from the Patient Health Questionnaire (PHQ-9), which measures depression severity in past 14 days. Scores can range from 0 to 27, with scores of 0-4 classified as minimal depression, 5-9 as mild depression; 10-14 as moderate depression; 15-19 as moderately severe depression, and ≥ 20 as severe depression). Each item on the scale can be scored from 0 (not at all) to 3 (nearly everyday).
Time Frame
3 months
Title
Fidelity - BIOS score for audio recordings (1)
Description
Mean score on the first 10 items of the Brief Intervention Observation Sheet (BIOS) per provider from a sample of audio recorded brief interventions (BI). Scores can range from 0-10, with higher scores indicating better performance.
Time Frame
During the 12-month implementation phase
Title
Fidelity - BIOS score for audio recordings (2)
Description
Mean score on the 11th item of the Brief Intervention Observation Sheet (BIOS) per provider from a sample of audio recorded brief interventions (BI). The 11th item reflects how well the provider use a motivational style. Scores can range from 1-7, with higher scores indicating better performance.
Time Frame
During the 12-month implementation phase
Title
Incidence of sex under influence of alcohol/drugs (T0)
Description
Any incidence of sex under influence of alcohol/drugs in past 30 days
Time Frame
Baseline
Title
Incidence of sex under influence of alcohol/drugs (T1)
Description
Any incidence of sex under influence of alcohol/drugs in past 30 days
Time Frame
30 days
Title
Incidence of sex under influence of alcohol/drugs (T2)
Description
Any incidence of sex under influence of alcohol/drugs in past 30 days
Time Frame
3 months
Title
Number of days of drug use (T0)
Description
Number of days of drug use in past 30 days
Time Frame
Baseline
Title
Number of days of drug use (T1)
Description
Number of days of drug use in past 30 days
Time Frame
30 days
Title
Number of days of drug use (T2)
Description
Number of days of drug use in past 30 days
Time Frame
3 months
Title
Number of events of sex under influence of alcohol/drugs (T0)
Description
Number of events of sex under influence of alcohol/drugs in past 30 days
Time Frame
Baseline
Title
Number of events of sex under influence of alcohol/drugs (T1)
Description
Number of events of sex under influence of alcohol/drugs in past 30 days
Time Frame
30 days
Title
Number of events of sex under influence of alcohol/drugs (T2)
Description
Number of events of sex under influence of alcohol/drugs in past 30 days
Time Frame
3 months
Title
Number of recordings to achieve competency
Description
Number of audio recordings needed to achieve competency as rated by SBIRT trainers using the Brief Intervention Observation Sheet (BIOS)
Time Frame
During the 6-month preparation phase
Title
Patients receiving BI (IP)
Description
Percent of patients in each clinic out of all who screen positive, who receive a brief intervention during the implementation phase (IP)
Time Frame
During the 12-month implementation phase
Title
Patients receiving BI (SP)
Description
Patients receiving BI (SP)
Time Frame
During the 12-month sustainment phase
Title
SBIRT use (IP)
Description
Number/proportion of providers in each clinic using SBIRT (implementation phase)
Time Frame
During the 12-month implementation phase
Title
SBIRT use (SP)
Description
Number/proportion of clinics and of providers in each clinic using SBIRT (sustainment phase)
Time Frame
During the 12-month sustainment phase
Secondary Outcome Measure Information:
Title
AUDIT-C score (T0)
Description
Score on screening measure for risky drinking; adjusted to past 30 days. The Alcohol Use Disorders Identification Test-Concise (AUDIT-C) is a brief alcohol screening instrument that reliably identifies persons who are hazardous drinkers or have active alcohol use disorders (including alcohol abuse or dependence). The AUDIT-C is a modified version of the 10 question AUDIT instrument. The AUDIT-C has 3 questions and is scored on a scale of 0-12. Each AUDIT-C question has 5 answer choices valued from 0 points to 4 points. In men, a score of 4 or more is considered positive, optimal for identifying hazardous drinking or active alcohol use disorders. In women, a score of 3 or more is considered positive. Generally, the higher the score, the more likely it is that a person's drinking is affecting his or her safety.
Time Frame
Baseline
Title
AUDIT-C score (T1)
Description
Score on screening measure for risky drinking; adjusted to past 30 days. The Alcohol Use Disorders Identification Test-Concise (AUDIT-C) is a brief alcohol screening instrument that reliably identifies persons who are hazardous drinkers or have active alcohol use disorders (including alcohol abuse or dependence). The AUDIT-C is a modified version of the 10 question AUDIT instrument. The AUDIT-C has 3 questions and is scored on a scale of 0-12. Each AUDIT-C question has 5 answer choices valued from 0 points to 4 points. In men, a score of 4 or more is considered positive, optimal for identifying hazardous drinking or active alcohol use disorders. In women, a score of 3 or more is considered positive. Generally, the higher the score, the more likely it is that a person's drinking is affecting his or her safety.
Time Frame
30 days
Title
AUDIT-C score (T2)
Description
Score on screening measure for risky drinking; adjusted to past 30 days. The Alcohol Use Disorders Identification Test-Concise (AUDIT-C) is a brief alcohol screening instrument that reliably identifies persons who are hazardous drinkers or have active alcohol use disorders (including alcohol abuse or dependence). The AUDIT-C is a modified version of the 10 question AUDIT instrument. The AUDIT-C has 3 questions and is scored on a scale of 0-12. Each AUDIT-C question has 5 answer choices valued from 0 points to 4 points. In men, a score of 4 or more is considered positive, optimal for identifying hazardous drinking or active alcohol use disorders. In women, a score of 3 or more is considered positive. Generally, the higher the score, the more likely it is that a person's drinking is affecting his or her safety.
Time Frame
3 months
Title
Anxiety score (T0)
Description
Score on the Generalized Anxiety Disorder 7-item (GAD-7) scale, which measures anxiety severity. Each item is scored on a scale of 0 (not at all) to 3 (nearly every day), with higher scores indicating higher levels of anxiety based on past 14 days. A score of 0-4 is classified as minimal anxiety, 5-9 as mild anxiety, 10-14 as moderate anxiety, and as 15-21 severe anxiety.
Time Frame
Baseline
Title
Anxiety score (T1)
Description
Score on the Generalized Anxiety Disorder 7-item (GAD-7) scale, which measures anxiety severity. Each item is scored on a scale of 0 (not at all) to 3 (nearly every day), with higher scores indicating higher levels of anxiety based on past 14 days. A score of 0-4 is classified as minimal anxiety, 5-9 as mild anxiety, 10-14 as moderate anxiety, and as 15-21 severe anxiety.
Time Frame
30 days
Title
Anxiety score (T2)
Description
Score on the Generalized Anxiety Disorder 7-item (GAD-7) scale, which measures anxiety severity. Each item is scored on a scale of 0 (not at all) to 3 (nearly every day), with higher scores indicating higher levels of anxiety based on past 14 days. A score of 0-4 is classified as minimal anxiety, 5-9 as mild anxiety, 10-14 as moderate anxiety, and as 15-21 severe anxiety.
Time Frame
3 months
Title
BIOS score (1)
Description
Each provider's score on the first 10 items of the Brief Intervention Observation Sheet (BIOS) on the last observation conducted during provider training. Scores can range from 0-10, with higher scores indicating better performance.
Time Frame
During the 6-month preparation phase
Title
BIOS score (2)
Description
Each provider's score on the 11th item of the Brief Intervention Observation Sheet (BIOS) on the last observation conducted during provider training. Scores can range from 1-7, with higher scores indicating better performance.
Time Frame
During the 6-month preparation phase
Title
Days of alcohol use (T0)
Description
Number of days of alcohol use in past 30 days
Time Frame
Baseline
Title
Days of alcohol use (T1)
Description
Number of days of alcohol use in past 30 days
Time Frame
30 days
Title
Days of alcohol use (T2)
Description
Number of days of alcohol use in past 30 days
Time Frame
3 months
Title
Days of binge drinking (T0)
Description
Number of days of binge drinking (defined as 4 or more drinks) in past 30 days
Time Frame
Baseline
Title
Days of binge drinking (T1)
Description
Number of days of binge drinking (defined as 4 or more drinks) in past 30 days
Time Frame
30 days
Title
Days of binge drinking (T2)
Description
Number of days of binge drinking (defined as 4 or more drinks) in past 30 days
Time Frame
3 months
Title
General self-reported health (T0)
Description
Likert rating of general self-reported health in past 30 days
Time Frame
Baseline
Title
General self-reported health (T1)
Description
Likert rating of general self-reported health in past 30 days
Time Frame
30 days
Title
General self-reported health (T2)
Description
Likert rating of general self-reported health in past 30 days
Time Frame
3 months
Title
Incidence of condom nonuse (T0)
Description
Any incidence of condom nonuse monogamous encounters among women not intending pregnancy in past 30 days
Time Frame
Baseline
Title
Incidence of condom nonuse (T1)
Description
Any incidence of condom nonuse monogamous encounters among women not intending pregnancy in past 30 days
Time Frame
30 days
Title
Incidence of condom nonuse (T2)
Description
Any incidence of condom nonuse monogamous encounters among women not intending pregnancy in past 30 days
Time Frame
3 months
Title
Incidence of contraceptive nonuse (T0)
Description
Any incidence of contraceptive nonuse monogamous encounters among women not intending pregnancy in past 30 days
Time Frame
Baseline
Title
Incidence of contraceptive nonuse (T1)
Description
Any incidence of contraceptive nonuse monogamous encounters among women not intending pregnancy in past 30 days
Time Frame
30 days
Title
Incidence of contraceptive nonuse (T2)
Description
Any incidence of contraceptive nonuse monogamous encounters among women not intending pregnancy in past 30 days
Time Frame
3 months
Title
Incidence of regretted/nonconsensual sex and sexual violence (T0)
Description
Any incidence of non-consensual sex, regretted sex, or sexual violence in past 30 days
Time Frame
Baseline
Title
Incidence of regretted/nonconsensual sex and sexual violence (T1)
Description
Any incidence of non-consensual sex, regretted sex, or sexual violence in past 30 days
Time Frame
30 days
Title
Incidence of regretted/nonconsensual sex and sexual violence (T2)
Description
Any incidence of non-consensual sex, regretted sex, or sexual violence in past 30 days
Time Frame
3 months
Title
NIDA ASSIST score (T0)
Description
Score on the National Institute of Drug Addiction-Modified Alcohol, Smoking and Substance Involvement Screening Test (NIDA-Modified ASSIST) screening measure for risky drinking; adjusted to past 30 days. Scores range from 0 to 390, with higher scores indicating greater risk. A score of 0-3 is considered lower risk, 4-26 is considered moderate risk, and 27 and over is considered high risk.
Time Frame
Baseline
Title
NIDA ASSIST score (T1)
Description
Score on the National Institute of Drug Addiction-Modified Alcohol, Smoking and Substance Involvement Screening Test (NIDA-Modified ASSIST) screening measure for risky drinking; adjusted to past 30 days. Scores range from 0 to 390, with higher scores indicating greater risk. A score of 0-3 is considered lower risk, 4-26 is considered moderate risk, and 27 and over is considered high risk.
Time Frame
30 days
Title
NIDA ASSIST score (T2)
Description
Score on the National Institute of Drug Addiction-Modified Alcohol, Smoking and Substance Involvement Screening Test (NIDA-Modified ASSIST) screening measure for risky drinking; adjusted to past 30 days. Scores range from 0 to 390, with higher scores indicating greater risk. A score of 0-3 is considered lower risk, 4-26 is considered moderate risk, and 27 and over is considered high risk.
Time Frame
3 months
Title
Number of events of condom nonuse (T0)
Description
Number of events of condom nonuse monogamous encounters among women not intending pregnancy in past 30 days
Time Frame
Baseline
Title
Number of events of condom nonuse (T1)
Description
Number of events of condom nonuse monogamous encounters among women not intending pregnancy in past 30 days
Time Frame
30 days
Title
Number of events of condom nonuse (T2)
Description
Number of events of condom nonuse monogamous encounters among women not intending pregnancy in past 30 days
Time Frame
3 months
Title
Number of events of contraceptive nonuse (T0)
Description
Number of events of contraceptive nonuse monogamous encounters among women not intending pregnancy in past 30 days
Time Frame
Baseline
Title
Number of events of contraceptive nonuse (T1)
Description
Number of events of contraceptive nonuse monogamous encounters among women not intending pregnancy in past 30 days
Time Frame
30 days
Title
Number of events of contraceptive nonuse (T2)
Description
Number of events of contraceptive nonuse monogamous encounters among women not intending pregnancy in past 30 days
Time Frame
3 months
Title
Number of events of regretted/nonconsensual sex and sexual violence (T0)
Description
Number of events of non-consensual sex, regretted sex, or sexual violence in past 30 days
Time Frame
Baseline
Title
Number of events of regretted/nonconsensual sex and sexual violence (T1)
Description
Number of events of non-consensual sex, regretted sex, or sexual violence in past 30 days
Time Frame
30 days
Title
Number of events of regretted/nonconsensual sex and sexual violence (T2)
Description
Number of events of non-consensual sex, regretted sex, or sexual violence in past 30 days
Time Frame
3 months
Title
Patients receiving referral (IP)
Description
Percent of patients who screen at a severe level of alcohol use, who receive a referral during the implementation phase (IP)
Time Frame
During the 12-month implementation phase
Title
Patients receiving referral (SP)
Description
Percent of patients who screen at a severe level of alcohol use, who receive a referral during the sustainment phase (SP)
Time Frame
During the 12-month sustainment phase
Title
Patients screened (IP)
Description
Percent of patients out of all patients seen who are screened during the implementation phase (IP)
Time Frame
During the 12-month implementation phase
Title
Patients screened (SP)
Description
Percent of patients out of all patients seen who are screened during the sustainment phase (SP)
Time Frame
During the 12-month sustainment phase
Title
Quality of life score (T0)
Description
Score on the 12-Item Short Form Health Survey, which measures physical and mental health functioning in past 30 days. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.
Time Frame
Baseline
Title
Quality of life score (T1)
Description
Score on the 12-Item Short Form Health Survey, which measures physical and mental health functioning in past 30 days. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.
Time Frame
30 days
Title
Quality of life score (T2)
Description
Score on the 12-Item Short Form Health Survey, which measures physical and mental health functioning in past 30 days. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.
Time Frame
3 months
Title
SBIRT knowledge
Description
Score on University of Missouri-Kansas City Screening & Brief Intervention Knowledge Assessment. Will b be completed by providers undergoing training in SBIRT. Scores range from 0-20, with higher scores indicating more knowledge of SBIRT.
Time Frame
During the 6-month preparation phase
Title
STI incidence (T0)
Description
Any incidence of a sexually transmitted infection (STI) in past 30 days
Time Frame
Baseline
Title
STI incidence (T1)
Description
Any incidence of a sexually transmitted infection (STI) in past 30 days
Time Frame
30 days
Title
STI incidence (T2)
Description
Any incidence of a sexually transmitted infection (STI) in past 30 days
Time Frame
3 months
Title
Unintended pregnancy (T0)
Description
Any incidence of unintended pregnancy in past 30 days
Time Frame
Baseline
Title
Unintended pregnancy (T1)
Description
Any incidence of unintended pregnancy in past 30 days
Time Frame
30 days
Title
Unintended pregnancy (T2)
Description
Any incidence of unintended pregnancy in past 30 days
Time Frame
3 months
Title
Well-being score (T0)
Description
Score on the World Health Organization-Five Well-Being Index (WHO-5), a five-item scale that measures subjective psychological well-being in past 14 days. Scores range from 0-5, with 0 representing the worst possible and 25 representing the best possible quality of life.
Time Frame
Baseline
Title
Well-being score (T1)
Description
Score on the World Health Organization-Five Well-Being Index (WHO-5), a five-item scale that measures subjective psychological well-being in past 14 days. Scores range from 0-5, with 0 representing the worst possible and 25 representing the best possible quality of life.
Time Frame
30 days
Title
Well-being score (T2)
Description
Score on the World Health Organization-Five Well-Being Index (WHO-5), a five-item scale that measures subjective psychological well-being in past 14 days. Scores range from 0-5, with 0 representing the worst possible and 25 representing the best possible quality of life.
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Over the age of 18 years U.S. residing Have internet access (own a computer or smart phone) Screen positive to one or more risky alcohol and substance use behaviors as determined by our standardized abbreviated instruments Exclusion Criteria: - Not capable of communicating (reading, speaking, writing) in English or Spanish
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kelli S Hall, PhD MS
Phone
212-305-4805
Email
ksh2110@cumc.columbia.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Jessica LaHote, MPH
Phone
212-305-4805
Email
jl5348@cumc.columbia.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kelli S Hall, MD
Organizational Affiliation
Columbia University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Justine Welsh, MD
Organizational Affiliation
Emory University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Greater Boston Health Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Facility Name
Metro West Health Center
City
Marlborough
State/Province
Massachusetts
ZIP/Postal Code
01752
Country
United States
Facility Name
Western Massachusetts Health Center
City
Springfield
State/Province
Massachusetts
ZIP/Postal Code
01107
Country
United States
Facility Name
Central Massachusetts Health Center
City
Worcester
State/Province
Massachusetts
ZIP/Postal Code
01609
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Per the NIAAA Exemption Request Committee's determination electronic health records/administrative records data components will not be shared. Quantitative survey data will be shared.
IPD Sharing Time Frame
Data will be made available by October 1st, 2024 and will be available indefinitely.
IPD Sharing Access Criteria
Anyone who wishes to access the data will be able to do so.
Citations:
PubMed Identifier
26401713
Citation
Tan CH, Denny CH, Cheal NE, Sniezek JE, Kanny D. Alcohol use and binge drinking among women of childbearing age - United States, 2011-2013. MMWR Morb Mortal Wkly Rep. 2015 Sep 25;64(37):1042-6. doi: 10.15585/mmwr.mm6437a3.
Results Reference
background
PubMed Identifier
12728126
Citation
Naimi TS, Lipscomb LE, Brewer RD, Gilbert BC. Binge drinking in the preconception period and the risk of unintended pregnancy: implications for women and their children. Pediatrics. 2003 May;111(5 Pt 2):1136-41.
Results Reference
background
PubMed Identifier
11755563
Citation
Thomas AG, Brodine SK, Shaffer R, Shafer MA, Boyer CB, Putnam S, Schachter J. Chlamydial infection and unplanned pregnancy in women with ready access to health care. Obstet Gynecol. 2001 Dec;98(6):1117-23.
Results Reference
background
PubMed Identifier
11825863
Citation
Kesmodel U, Wisborg K, Olsen SF, Henriksen TB, Secher NJ. Moderate alcohol intake in pregnancy and the risk of spontaneous abortion. Alcohol Alcohol. 2002 Jan-Feb;37(1):87-92. doi: 10.1093/alcalc/37.1.87.
Results Reference
background
PubMed Identifier
12460095
Citation
Iyasu S, Randall LL, Welty TK, Hsia J, Kinney HC, Mandell F, McClain M, Randall B, Habbe D, Wilson H, Willinger M. Risk factors for sudden infant death syndrome among northern plains Indians. JAMA. 2002 Dec 4;288(21):2717-23. doi: 10.1001/jama.288.21.2717. Erratum In: JAMA. 2003 Jan 15;289(3):303.
Results Reference
background
PubMed Identifier
21036512
Citation
Heil SH, Jones HE, Arria A, Kaltenbach K, Coyle M, Fischer G, Stine S, Selby P, Martin PR. Unintended pregnancy in opioid-abusing women. J Subst Abuse Treat. 2011 Mar;40(2):199-202. doi: 10.1016/j.jsat.2010.08.011. Epub 2010 Oct 30.
Results Reference
background
PubMed Identifier
28278146
Citation
Ko JY, Wolicki S, Barfield WD, Patrick SW, Broussard CS, Yonkers KA, Naimon R, Iskander J. CDC Grand Rounds: Public Health Strategies to Prevent Neonatal Abstinence Syndrome. MMWR Morb Mortal Wkly Rep. 2017 Mar 10;66(9):242-245. doi: 10.15585/mmwr.mm6609a2.
Results Reference
background
PubMed Identifier
32293827
Citation
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Examination of the Integration of Opioid and Infectious Disease Prevention Efforts in Select Programs. Opportunities to Improve Opioid Use Disorder and Infectious Disease Services: Integrating Responses to a Dual Epidemic. Washington (DC): National Academies Press (US); 2020 Jan 23. Available from http://www.ncbi.nlm.nih.gov/books/NBK555809/
Results Reference
background
PubMed Identifier
26690290
Citation
Terplan M, Lawental M, Connah MB, Martin CE. Reproductive Health Needs Among Substance Use Disorder Treatment Clients. J Addict Med. 2016 Jan-Feb;10(1):20-5. doi: 10.1097/ADM.0000000000000175.
Results Reference
background
PubMed Identifier
25739018
Citation
Cornford CS, Close HJ, Bray R, Beere D, Mason JM. Contraceptive use and pregnancy outcomes among opioid drug-using women: a retrospective cohort study. PLoS One. 2015 Mar 4;10(3):e0116231. doi: 10.1371/journal.pone.0116231. eCollection 2015.
Results Reference
background
PubMed Identifier
23972743
Citation
Stanhope TJ, Gill LA, Rose C. Chronic opioid use during pregnancy: maternal and fetal implications. Clin Perinatol. 2013 Sep;40(3):337-50. doi: 10.1016/j.clp.2013.05.015. Epub 2013 Jul 4.
Results Reference
background
PubMed Identifier
21376165
Citation
Kellogg A, Rose CH, Harms RH, Watson WJ. Current trends in narcotic use in pregnancy and neonatal outcomes. Am J Obstet Gynecol. 2011 Mar;204(3):259.e1-4. doi: 10.1016/j.ajog.2010.12.050.
Results Reference
background
PubMed Identifier
31856949
Citation
Pinedo M. Help seeking behaviors of Latinos with substance use disorders who perceive a need for treatment: Substance abuse versus mental health treatment services. J Subst Abuse Treat. 2020 Feb;109:41-45. doi: 10.1016/j.jsat.2019.11.006. Epub 2019 Nov 14.
Results Reference
background
PubMed Identifier
28196680
Citation
Hadland SE, Copelas SH, Harris SK. Trajectories of Substance Use Frequency among Adolescents Seen in Primary Care: Implications for Screening. J Pediatr. 2017 May;184:178-185. doi: 10.1016/j.jpeds.2017.01.033. Epub 2017 Feb 10.
Results Reference
background
PubMed Identifier
28685885
Citation
Chavez LJ, Kelleher KJ, Matson SC, Wickizer TM, Chisolm DJ. Mental Health and Substance Use Care Among Young Adults Before and After Affordable Care Act (ACA) Implementation: A Rural and Urban Comparison. J Rural Health. 2018 Dec;34(1):42-47. doi: 10.1111/jrh.12258. Epub 2017 Jul 7.
Results Reference
background
PubMed Identifier
29346340
Citation
Robbins C, Boulet SL, Morgan I, D'Angelo DV, Zapata LB, Morrow B, Sharma A, Kroelinger CD. Disparities in Preconception Health Indicators - Behavioral Risk Factor Surveillance System, 2013-2015, and Pregnancy Risk Assessment Monitoring System, 2013-2014. MMWR Surveill Summ. 2018 Jan 19;67(1):1-16. doi: 10.15585/mmwr.ss6701a1. Erratum In: MMWR Morb Mortal Wkly Rep. 2018 Apr 27;67(16):479.
Results Reference
background
PubMed Identifier
32456604
Citation
Hayes DK, Robbins CL, Ko JY. Trends in Selected Chronic Conditions and Related Risk Factors Among Women of Reproductive Age: Behavioral Risk Factor Surveillance System, 2011-2017. J Womens Health (Larchmt). 2020 Dec;29(12):1576-1585. doi: 10.1089/jwh.2019.8275. Epub 2020 May 22.
Results Reference
background
PubMed Identifier
32278371
Citation
Hall KS, Samari G, Garbers S, Casey SE, Diallo DD, Orcutt M, Moresky RT, Martinez ME, McGovern T. Centring sexual and reproductive health and justice in the global COVID-19 response. Lancet. 2020 Apr 11;395(10231):1175-1177. doi: 10.1016/S0140-6736(20)30801-1. No abstract available.
Results Reference
background
PubMed Identifier
22525931
Citation
ACOG Committee on Health Care for Underserved Women; American Society of Addiction Medicine. ACOG Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol. 2012 May;119(5):1070-6. doi: 10.1097/AOG.0b013e318256496e.
Results Reference
background
PubMed Identifier
23122212
Citation
Frost JJ, Gold RB, Bucek A. Specialized family planning clinics in the United States: why women choose them and their role in meeting women's health care needs. Womens Health Issues. 2012 Nov-Dec;22(6):e519-25. doi: 10.1016/j.whi.2012.09.002.
Results Reference
background
PubMed Identifier
27825589
Citation
Hall KS, Harris LH, Dalton VK. Women's Preferred Sources for Primary and Mental Health Care: Implications for Reproductive Health Providers. Womens Health Issues. 2017 Mar-Apr;27(2):196-205. doi: 10.1016/j.whi.2016.09.014. Epub 2016 Nov 4.
Results Reference
background
PubMed Identifier
10672110
Citation
Friedmann PD, McCullough D, Chin MH, Saitz R. Screening and intervention for alcohol problems. A national survey of primary care physicians and psychiatrists. J Gen Intern Med. 2000 Feb;15(2):84-91. doi: 10.1046/j.1525-1497.2000.03379.x.
Results Reference
background
PubMed Identifier
27373599
Citation
Wright TE, Terplan M, Ondersma SJ, Boyce C, Yonkers K, Chang G, Creanga AA. The role of screening, brief intervention, and referral to treatment in the perinatal period. Am J Obstet Gynecol. 2016 Nov;215(5):539-547. doi: 10.1016/j.ajog.2016.06.038. Epub 2016 Jul 1.
Results Reference
background
PubMed Identifier
25127073
Citation
Rahm AK, Boggs JM, Martin C, Price DW, Beck A, Backer TE, Dearing JW. Facilitators and Barriers to Implementing Screening, Brief Intervention, and Referral to Treatment (SBIRT) in Primary Care in Integrated Health Care Settings. Subst Abus. 2015;36(3):281-8. doi: 10.1080/08897077.2014.951140. Epub 2014 Aug 15.
Results Reference
background
PubMed Identifier
26230758
Citation
Hettema J, Cockrell S, Russo J, Corder-Mabe J, Yowell-Many A, Chisholm C, Ingersoll K. Missed Opportunities: Screening and Brief Intervention for Risky Alcohol Use in Women's Health Settings. J Womens Health (Larchmt). 2015 Aug;24(8):648-54. doi: 10.1089/jwh.2014.4961. Epub 2015 Jul 31.
Results Reference
background
PubMed Identifier
30284173
Citation
Goldstein KM, Zullig LL, Dedert EA, Alishahi Tabriz A, Brearly TW, Raitz G, Sata SS, Whited JD, Bosworth HB, Gordon AM, Nagi A, Williams JW Jr, Gierisch JM. Telehealth Interventions Designed for Women: an Evidence Map. J Gen Intern Med. 2018 Dec;33(12):2191-2200. doi: 10.1007/s11606-018-4655-8. Epub 2018 Oct 3.
Results Reference
background
PubMed Identifier
26297297
Citation
Boudreaux ED, Haskins B, Harralson T, Bernstein E. The remote brief intervention and referral to treatment model: Development, functionality, acceptability, and feasibility. Drug Alcohol Depend. 2015 Oct 1;155:236-42. doi: 10.1016/j.drugalcdep.2015.07.014. Epub 2015 Jul 23.
Results Reference
background
PubMed Identifier
34635178
Citation
Becker SJ, Murphy CM, Hartzler B, Rash CJ, Janssen T, Roosa M, Madden LM, Garner BR. Project MIMIC (Maximizing Implementation of Motivational Incentives in Clinics): A cluster-randomized type 3 hybrid effectiveness-implementation trial. Addict Sci Clin Pract. 2021 Oct 12;16(1):61. doi: 10.1186/s13722-021-00268-0.
Results Reference
background
PubMed Identifier
29149909
Citation
Garner BR, Zehner M, Roosa MR, Martino S, Gotham HJ, Ball EL, Stilen P, Speck K, Vandersloot D, Rieckmann TR, Chaple M, Martin EG, Kaiser D, Ford JH 2nd. Testing the implementation and sustainment facilitation (ISF) strategy as an effective adjunct to the Addiction Technology Transfer Center (ATTC) strategy: study protocol for a cluster randomized trial. Addict Sci Clin Pract. 2017 Nov 17;12(1):32. doi: 10.1186/s13722-017-0096-7.
Results Reference
background
PubMed Identifier
36189179
Citation
Garner BR, Gotham HJ, Chaple M, Martino S, Ford Ii JH, Roosa MR, Speck KJ, Vandersloot D, Bradshaw M, Ball EL, Toro AK, Griggs C, Tueller SJ. The implementation and sustainment facilitation strategy improved implementation effectiveness and intervention effectiveness: Results from a cluster-randomized, type 2 hybrid trial. Implement Res Pract. 2020 Jan-Dec;1:2633489520948073. doi: 10.1177/2633489520948073. Epub 2020 Sep 7.
Results Reference
background
Citation
Gotham HJ, Wilson K, Carlson K, Rodriguez G, Kuofie A, Witt J. Implementing Substance Use Screening in Family Planning. J Nurse Pract. 2019;15(4):306-310.
Results Reference
background

Learn more about this trial

Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years

We'll reach out to this number within 24 hrs